Format

Send to

Choose Destination
Cell Stem Cell. 2017 Jul 6;21(1):14-17. doi: 10.1016/j.stem.2017.06.005.

The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery.

Author information

1
Department of Integrative Pharmacology (ZR13), Integrated Science and Technology, AbbVie, Building AP-9A LL, 1 North Waukegan Road, North Chicago, IL 60064-6118, USA. Electronic address: gary.gintant@abbvie.com.
2
Coyne Scientific, 58 Edgewood Avenue NE, Atlanta, GA 30303, USA.
3
Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
4
Division of Applied Regulatory Science, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.

Abstract

Nonclinical studies of drug effects with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide new possibilities for evaluating drug safety and efficacy. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm provides lessons from the cardiac field that also apply to drug studies with other stem cell-based assays.

PMID:
28686863
DOI:
10.1016/j.stem.2017.06.005
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center